NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Alpha Fusion Inc.

Alpha Fusion Inc.

Private
OsakaHealthcare & Life Scienceshttps://alpha-fusion.com/

Last Round

Series B

Oct 9, 2024

Total Funding Raised

$10.04M

Company Overview

Alpha Fusion Inc. is a biotechnology company developing targeted alpha therapy (TAT) using astatine-211 for cancer treatment.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

targeted alpha therapyTATradiopharmaceuticalsAstatine-211At-211cancer treatmentprecision medicineoncologyradiotherapydrug discoveryclinical trialsnuclear medicinebiotechnologytheranosticstargeted cancer therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Alpha Fusion Inc. Comparables

Compare Alpha Fusion Inc. with similar companies based on industry and business-model similarity.

Alpha Fusion Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Atonco
86%
Atley Solutions
75%
Bristol Myers Squibb
69%

Alpha Fusion Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BOct 9, 2024
Series AMar 8, 2023

Alpha Fusion Inc. Investors

Notable investors and investment history

Alpha Fusion Inc. investors
InvestorRounds
Kobe University CapitalSeries B
Global Brain CorporationSeries A
Joyo Capital PartnersSeries B
Japan Science and Technology AgencySeries A
Osaka University Venture Capital Co., Ltd.Series A, Series B
SBI Investment Co., Ltd.Series B
D3 LLCSeries A, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 8, 2025

    Collaborating with Kobe City Medical Center General Hospital on an At-211 investigational drug supply system.

Alpha Fusion Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Alpha Fusion Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Alpha Fusion Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersOsaka
Employee Range8
Year Founded2021
Last FundingOct 9, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.